Reuters logo
BRIEF-Palatin Technologies signs agreement with Fosun Pharma
September 6, 2017 / 11:49 AM / 2 months ago

BRIEF-Palatin Technologies signs agreement with Fosun Pharma

Sept 6 (Reuters) - Palatin Technologies Inc

* Palatin Technologies announces signing of licensing agreement with Fosun Pharma rights to bremelanotide in China and other selected territories

* Palatin Technologies Inc - ‍under terms of agreement, Palatin will receive an upfront payment of $5.0 million​

* Palatin Technologies- New Drug Application (NDA) is anticipated to be filed with U.S. Food and Drug Administration (FDA) in Q1 of calendar year 2018

* Palatin Technologies Inc - ‍ under terms of agreement, Palatin will receive $7.5 million milestone based on regulatory approval in China​

* Palatin Technologies - has potential to receive up to $92.5 million in sales related milestones

* Palatin Technologies Inc - to receive high single-digit to low double-digit royalties on net sales in licensed territory Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below